Skip to main content

Table 5 Effect of 2013 compared to 2010 on analyte concentrations in infected and uninfected individuals

From: Changing plasma cytokine, chemokine and growth factor profiles upon differing malaria transmission intensities

AnalytesCoefficient (CI)p-valuep-value BHCoefficient (CI) adjustedp-value adjusted*p-value BH adjusted*
Infected
 IL-1β− 1.248 (− 1.463, − 1.034)< 0.001< 0.001− 1.311 (− 1.543, − 1.079)< 0.001< 0.001
 IL-1RA− 0.638 (− 0.743, − 0.534)< 0.001< 0.001− 0.67 (− 0.781, − 0.559)< 0.001< 0.001
 TNF− 0.666 (− 0.842, − 0.49)< 0.001< 0.001− 0.678 (− 0.867, − 0.489)< 0.001< 0.001
 IL-6− 1.945 (− 2.144, − 1.746)< 0.001< 0.001− 2.023 (− 2.239, − 1.807)< 0.001< 0.001
 IFN-α− 0.025 (− 0.093, 0.043)0.4700.486− 0.026 (− 0.097, 0.046)0.4810.505
 IFN-γ− 0.036 (− 0.099, 0.028)0.2680.321− 0.039 (− 0.103, 0.026)0.2350.293
 IL-12− 0.035 (− 0.096, 0.027)0.2650.321− 0.029 (− 0.092, 0.033)0.3580.410
 IL-17− 0.147 (− 0.288, − 0.006)0.0410.057− 0.149 (− 0.295, − 0.002)0.0470.064
 IL-10− 0.227 (− 0.391, − 0.063)0.0070.010− 0.235 (− 0.407, − 0.063)0.0080.012
 IL-13− 0.119 (− 0.22, − 0.017)0.0220.031− 0.149 (− 0.252, − 0.046)0.0050.009
 IL-4− 0.076 (− 0.193, 0.042)0.2050.267− 0.073 (− 0.196, 0.051)0.2450.295
 IL-5− 0.018 (− 0.167, 0.132)0.8150.815− 0.033 (− 0.187, 0.121)0.6730.673
 IL-2− 0.064 (− 0.181, 0.052)0.2780.321− 0.056 (− 0.177, 0.066)0.3690.410
 IL-2R− 0.126 (− 0.21, − 0.042)0.0030.006− 0.123 (− 0.202, − 0.043)0.0030.005
 IL-15− 0.182 (− 0.302, − 0.063)0.0030.006− 0.168 (− 0.294, − 0.043)0.0090.013
 IL-7− 0.819 (− 1.228, − 0.411)< 0.001< 0.001− 0.858 (− 1.279, − 0.436)< 0.001< 0.001
 Eotaxin− 0.043 (− 0.145, 0.058)0.4010.430− 0.066 (− 0.173, 0.04)0.2210.288
 IL-8− 1.769 (− 1.956, − 1.582)< 0.001< 0.001− 1.868 (− 2.067, − 1.669)< 0.001< 0.001
 IP-10− 0.242 (− 0.369, − 0.116)< 0.0010.001− 0.227 (− 0.36, − 0.094)0.0010.002
 MCP1− 0.29 (− 0.384, − 0.196)< 0.001< 0.001− 0.284 (− 0.385, − 0.182)< 0.001< 0.001
 MIG− 0.061 (− 0.181, 0.059)0.3130.348− 0.044 (− 0.169, 0.081)0.4880.505
 MIP-1α− 1.14 (− 1.335, − 0.946)<0.001< 0.001− 1.2 (− 1.41, − 0.991)< 0.001< 0.001
 MIP-1β− 1.413 (− 1.565, − 1.26)< 0.001< 0.001− 1.454 (− 1.622, − 1.287)< 0.001< 0.001
 RANTES0.143 (0.056, 0.23)0.0010.0030.109 (0.018, 0.201)0.0190.027
 EGF− 0.61 (− 0.778, − 0.442)< 0.001< 0.001− 0.684 (− 0.858, − 0.511)< 0.001< 0.001
 FGF− 0.754 (− 1.04, − 0.467)< 0.001< 0.001− 0.935 (− 1.222, − 0.648)< 0.001< 0.001
 G-CSF− 0.1 (− 0.169, − 0.032)0.0040.006− 0.096 (− 0.167, − 0.026)0.0080.012
 GM-CSF− 0.291 (− 0.462, − 0.12)0.0010.002− 0.345 (− 0.524, − 0.167)< 0.001< 0.001
 HGF− 0.16 (− 0.268, − 0.053)0.0040.006− 0.154 (− 0.261, − 0.046)0.0050.009
 VEGF− 0.913 (− 1.057, − 0.769)< 0.001< 0.001− 0.967 (− 1.118, − 0.816)< 0.001< 0.001
Uninfected
 IL-1β− 2.586 (− 2.949, − 2.223)< 0.001< 0.001− 2.551 (− 2.961, − 2.14)< 0.001< 0.001
 IL-1RA− 0.501 (− 0.597, − 0.406)< 0.001< 0.001− 0.523 (− 0.628, − 0.418)< 0.001< 0.001
 TNF− 0.684 (− 0.877, − 0.49)< 0.001< 0.001− 0.699 (− 0.917, − 0.48)< 0.001< 0.001
 IL-6− 2.876 (− 3.129, − 2.623)< 0.001< 0.001− 2.878 (− 3.162, − 2.595)< 0.001< 0.001
 IFN-α− 0.291 (− 0.344, − 0.239)< 0.001< 0.001− 0.288 (− 0.347, − 0.23)< 0.001< 0.001
 IFN-γ0.002 (− 0.076, 0.08)0.9600.960− 0.001 (− 0.087, 0.085)0.9750.975
 IL-12− 0.129 (− 0.19, − 0.068)< 0.001< 0.001− 0.158 (− 0.217, − 0.098)< 0.001< 0.001
 IL-170.072 (− 0.085, 0.228)0.3690.4100.054 (− 0.121, 0.229)0.5440.628
 IL-10− 0.391 (− 0.53, − 0.251)< 0.001< 0.001− 0.376 (− 0.532, − 0.221)< 0.001< 0.001
 IL-13− 0.264 (− 0.404, − 0.123)< 0.001< 0.001− 0.272 (− 0.432, − 0.112)0.0010.001
 IL-4− 0.245 (− 0.342, − 0.148)< 0.001< 0.001− 0.233 (− 0.34, − 0.125)< 0.001< 0.001
 IL-50.046 (− 0.086, 0.178)0.4930.5100.066 (− 0.083, 0.215)0.3860.464
 IL-20.076 (− 0.13, 0.282)0.4670.5010.012 (− 0.201, 0.224)0.9140.946
 IL-2R− 0.12 (− 0.247, 0.007)0.0640.087− 0.195 (− 0.319, − 0.072)0.0020.003
 IL-15− 0.22 (− 0.546, 0.106)0.1840.224− 0.356 (− 0.711, − 0.001)0.0500.062
 IL-7− 0.868 (− 1.188, − 0.549)< 0.001< 0.001− 0.917 (− 1.264, − 0.579)< 0.001< 0.001
 Eotaxin− 0.081 (− 0.177, 0.015)0.0990.1290.011 (− 0.089, 0.112)0.8240.883
 IL-8− 2.096 (− 2.287, − 1.904)< 0.001< 0.001− 2.127 (− 2.339, − 1.916)< 0.001< 0.001
 IP-10− 0.343 (− 0.436, − 0.25)< 0.001< 0.001− 0.337 (− 0.441, − 0.233)< 0.001< 0.001
 MCP1− 0.527 (− 0.615, − 0.44)< 0.001< 0.001− 0.515 (− 0.614, − 0.416)< 0.001< 0.001
 MIG− 0.076 (− 0.215, 0.062)0.2790.322− 0.033 (− 0.186, 0.12)0.6730.748
 MIP-1α− 1.267 (− 1.442, − 1.093)< 0.001< 0.001− 1.299 (− 1.497, − 1.101)< 0.001< 0.001
 MIP-1β− 1.484 (− 1.629, − 1.349< 0.001< 0.001− 1.478 (− 1.638, − 1.319)< 0.001< 0.001
 RANTES0.129 (0.05, 0.209)0.0020.0020.164 (0.087, 0.241)< 0.001< 0.001
 EGF− 1.555 (− 1.855, − 1.255)< 0.001< 0.001− 1.682 (− 2.004, − 1.359)< 0.001< 0.001
 FGF− 0.201 (− 0.499, 0.098)0.1870.224− 0.336 (− 0.662,− 0.011)0.0430.056
 G-CSF− 0.211 (− 0.307, − 0.114)< 0.001< 0.001− 0.236 (− 0.341, − 0.131)< 0.001< 0.001
 GM-CSF− 0.195 (− 0.354, − 0.036)0.0170.024− 0.195 (0.374, − 0.016)0.0330.045
 HGF− 0.29 (− 0.364, − 0.215)< 0.001< 0.001− 0.305 (− 0.386, − 0.225)< 0.001< 0.001
 VEGF− 1.887 (− 2.159, − 1.614)< 0.001< 0.001− 1.938 (− 2.235, − 1.641)< 0.001< 0.001
  1. The effect of year on analyte concentrations was assessed through univariable l and multivariable (adjusted models) separate linear regressions for each analyte, with analyte concentration (pg/mL) as outcome and year (2013 vs 2010) as the predictor variable. The analysis is presented separately for the infected and uninfected subjects. BH: P-values adjusted for multiple testing by Benjamini–Hochberg
  2. P-values < 0.05 are in italic
  3. CI confidence intervals
  4. * Adjusted by age group and area